4E-BP1 Cancer Research Results

4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1: Click to Expand ⟱
Source:
Type: protein
4E-BP1 (eukaryotic translation initiation factor 4E-binding protein 1) is a protein that plays a crucial role in regulating cell growth, proliferation, and survival. It is a key downstream target of the mTOR (mechanistic target of rapamycin) signaling pathway, which is often dysregulated in cancer.
Phosphorylated and inactivated in: breast, lung, CRC, prostate, GBM, pancreatic, ovarian, melanoma, HCC.
The level of phosphorylation can impact the prognosis and treatment response.
Scientific Papers found: Click to Expand⟱
1008- Api,    Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW480
Wnt/(β-catenin)↓, β-catenin/ZEB1↓, TumAuto↑, Akt↓, mTOR↓, tumCV↓, TumCCA↑, TumAuto↑, p‑Akt↓, p‑p70S6↓, p‑4E-BP1↓,
463- CUR,    Curcumin induces autophagic cell death in human thyroid cancer cells
- in-vitro, Thyroid, K1 - in-vitro, Thyroid, FTC-133 - in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, 8505C
TumAuto↑, LC3II↑, Beclin-1/ATG6↑, p‑p38↑, p‑JNK↑, p‑ERK↑, p62↓, p‑PDK1 / PDPK1↓, p‑Akt↓, p‑p70S6↓, p‑PIK3R1↓, p‑S6↓, p‑4E-BP1↓,
6350- DRE,    Tracking Evidences of Dandelion for the Treatment of Cancer: From Chemical Composition, Bioactivity, Signaling Pathways in Cancer Cells to Perspective Study
- Review, Var, NA
AntiCan↑, *Bacteria↓, *Inflam↓, *antiOx↑, TumCCA↑, Apoptosis↑, MOMP↑, Cyt‑c↑, APAF1↑, Casp9↑, Casp3↑, MMP↓, Bcl-2↓, TumCMig↓, TumCI↓, Wnt↓, β-catenin/ZEB1↓, MMP2↓, MMP9↓, TumAuto↑, mTOR↓, 4E-BP1↓, Glycolysis↓, angioG↓,
948- Fuc,    Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia
- vitro+vivo, Bladder, T24/HTB-9 - in-vitro, Nor, HUVECs
p‑PI3k/Akt/mTOR↓, p‑p70S6↓, p‑4E-BP1↓, angioG↓, Hif1a↓, VEGF↑, TumCG↓, TumVol↓, TumW↓, Iron∅, ROS↓,
7553- HYP,    Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro
- in-vitro, NSCLC, A549 - in-vitro, Nor, BEAS-2B
LC3II↑, selectivity↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, p‑4E-BP1↓, p‑ERK↑, tumCV↓, Apoptosis↑,
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,
8237- LCA,    Role of Licochalcone A in Potential Pharmacological Therapy: A Review
- Review, Var, NA
*other↝, *Inflam↓, *Bacteria↓, *antiOx↑, *AntiP↑, *neuroP↑, *glucose↝, *lipid-P↓, PKCδ↓, P70S6K↓, Akt↓, ER Stress↑, Apoptosis↑, Ca+2↑, PI3K↓, mTOR↓, Casp3↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑PARP↑, cycD1/CCND1↑, ROS↑, CHOP/DDIT3↑, ERK↑, p38↑, JNK↓, IAP1↓, XIAP↓, survivin↓, cFLIP↓, RIP1↓, EGFR↓, MET↓, HER2/EBBR2↓, p‑4E-BP1↓, PERK↑, eIF2α↑, PD-L1↓, HK2↓, Glycolysis↓, Sp1/3/4↓, FasL↑, MMP↓, ATP↓, TumAuto↑, WEE1↑, P21↑, CDK1↓, TumCCA↑, TumCMig↓, TumCI↓, ABCG2↓, HSP90↓, T-Cell↑, CD4+↑, CD25+↑, FOXP3↑, Imm↝, *Inflam↓, *NF-kB↓, *NRF2↑, *AntiArt↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24/HTB-9
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31/PECAM-1↓, CA↓,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1/SREBF1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,

Showing Research Papers: 1 to 10 of 10

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 10

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   RUBCN↓, 1,   THEM4/CTMP↑, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   ULK1/ATG1↑, 1,   WEE1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

H2O2↓, 1,   Iron∅, 1,   MDA↑, 1,   ROS↓, 2,   ROS↑, 3,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   CDC2↓, 1,   CDC25↓, 1,   MMP↓, 3,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↓, 1,   p‑AMPK↑, 1,   ATG7↑, 1,   FASN↓, 1,   Glycolysis↓, 3,   HK2↓, 2,   PDK1 / PDPK1↓, 1,   p‑PDK1 / PDPK1↓, 1,   p‑PI3k/Akt/mTOR↓, 1,   p‑PIK3R1↓, 1,   p‑S6↓, 1,   p‑S6K↓, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   p‑Akt↓, 4,   APAF1↑, 2,   Apoptosis↑, 3,   mt-Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 4,   Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 3,   DR5↑, 1,   Fas↑, 1,   FasL↑, 1,   IAP1↓, 1,   JNK↓, 1,   p‑JNK↑, 1,   MDM2↓, 1,   MOMP↑, 1,   p38↑, 1,   p‑p38↑, 1,   RIP1↓, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   p70S6↓, 1,   p‑p70S6↓, 3,   Sp1/3/4↓, 2,   TSC2↑, 1,   p‑TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   eIF2α↓, 2,   eIF2α↑, 1,   ER Stress↑, 2,   HSP90↓, 1,   PERK↑, 2,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1/ATG6↑, 2,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 2,   p62↓, 1,   p62↑, 1,   TumAuto↑, 6,  

DNA Damage & Repair(tgid=10) ⓘ

p‑P53↑, 1,   cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↑, 1,   P21↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 4,   p‑4E-BP1↓, 6,   p‑cMET↑, 1,   ERK↓, 1,   ERK↑, 1,   p‑ERK↑, 2,   mTOR↓, 6,   p‑mTOR↓, 2,   P70S6K↓, 3,   p‑P70S6K↓, 1,   PI3K↓, 2,   TumCG↓, 2,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

CA↓, 1,   Ca+2↑, 2,   CD31/PECAM-1↓, 1,   MET↓, 1,   MMP-10↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   PKCδ↓, 2,   TSC1↑, 1,   TumCI↓, 4,   TumCMig↓, 4,   TumCP↓, 2,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   ATF4↑, 1,   EGFR↓, 2,   Hif1a↓, 4,   VEGF↓, 2,   VEGF↑, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↑, 1,   CD4+↑, 1,   FOXP3↑, 1,   Imm↑, 1,   Imm↝, 1,   PD-L1↓, 2,   T-Cell↑, 1,  

Protein Aggregation(tgid=19) ⓘ

PP2A↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 2,   BioEnh↑, 1,   Half-Life↝, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   HER2/EBBR2↓, 1,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   PRAS40↑, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 143

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   AntiP↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   lipid-P↓, 1,   NRF2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

glucose↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 3,   NF-kB↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 2,  
Total Targets: 11

Scientific Paper Hit Count for: 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1
2 Licochalcone A
1 Apigenin (mainly Parsley)
1 Curcumin
1 Dandelion Root
1 Fucoidan
1 Hyperoside
1 Magnolol
1 Pterostilbene
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:736  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page